Case report: intraductal tubulopapillary neoplasm of the pancreas with unique clear cell phenotype
© Ahls et al.; licensee BioMed Central Ltd. 2014
Received: 27 December 2013
Accepted: 10 January 2014
Published: 20 January 2014
Intraductal tubulopapillary neoplasms of the pancreas are very rare tumors characterized by intraductal tubulopapillary growth, ductal differentiation, scant intracellular mucin production and cellular dysplasia. Here, we report the first case of an intraductal tubulopapillary neoplasm of the pancreas with clear cell morphology. The tumor was detected during the diagnostic work-up of acute pancreatitis in a 43- year old female. Histological examination revealed a tumor with the typical architecture of an intraductal tubulopapillary neoplasm of the pancreas with tumor cells showing abundant clear cytoplasm and Di-PAS negativity. Immunohistochemistry revealed positivity for Pan-CK, CK7, CK8/18, MUC1, MUC6, carbonic anhydrase IX, CD10, EMA, β-catenin and e-cadherin. Sanger sequencing did not detect mutations for β-catenin, BRAF, KRAS, PIK3CA and GNAS. Altogether, histology, immunohistochemical expression profile (MUC1+, MUC6+, MUC2-, MUC5AC-, thrypsin-, chymotrypsin-, CDX2-) and sequencing results led to the diagnosis of intraductal tubulopapillary neoplasm. However, the neoplasm consisted of cells showing abundant clear cytoplasm, a morphological pattern not being described so far in the current classification of pancreatic intraductal neoplasms. Potential differential diagnosis and the molecular basis of clear cell morphology are discussed. In conclusion, we consider this tumor as intraductal tubulopapillary neoplasm of the pancreas with unique clear cell phenotype. After surgery and without adjuvant therapy, the patient’s clinical course has been uneventful for over two years now.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1051828790117127
KeywordsIntraductal tubulopapillary neoplasm Clear cell morphology Pancreatic neoplasm ITPN
The term “Intraductal tubulopapillary neoplasm (ITPN)” was introduced by Yamaguchi and colleagues in 2009. With less than 0.9% of all pancreatic exocrine neoplasms, ITPN is a rarity within pancreatic tumors . About 50% of ITPNs occur in the head, 35% grow diffusely and 15% are located in the tail of the pancreas. ITPN has been included into the WHO classification of 2010 and belongs to the group of intraductal neoplasms of the pancreas . Macroscopically, ITPN presents as a solid often obliterating intraductal mass with no visible secreted mucin. Microscopically, the tumor shows tubulopapillary growth with scanty cytoplasmic mucin, often combined with areas of necrosis . The neoplastic cells, cuboidal to columnar with enlarged nuclei, show features of high grade dysplasia and a variable mitotic index. Invasive carcinoma is present in up to 40% [1, 2]. Immunohistochemically ITPN demonstrates positivity for CK7, CK19, MUC1, MUC6 and SMAD4 while trypsin, MUC2, MUC5AC, fascin, p53 and β-catenin are negative. Molecular analyses reveal mutations for PIK3CA in one third of ITPNs but in contrast, mutations in KRAS and BRAF are not detectable [1, 3]. So far all reports of ITPN describe the cytoplasm of the ITPN cells as eosinophilic to amphophilic. To the best of our knowledge, this is the first report of ITPN with clear cell morphology.
Materials and methods
Histology and immunohistochemical analyses
Differential immunolabeling of intraductal neoplasms of the pancreas
Mucin 5 AC
Clear cell type ITPN (our case)
Sequencing for β-catenin, BRAF, KRAS, PIK3CA and GNAS
Genomic DNA was extracted from FFPE tumor tissue after manual macrodissection using the QIAamp DNA Micro kit (Qiagen, Hilden, Germany) according to the manufacturer’s recommendations. The following PCR primers were used for amplification of β-catenin (exon 3), BRAF (exon 15), KRAS (exon 2), PIK3CA (exons 2, 10 & 21) and GNAS (exons 8 & 9):
5′-CTGATTTGATGGAGTTGGAC-3′ (β-catenin-F), 5′-GAAAATCCCTGTTCCCACTC-3′ (β-catenin-R), 5′-AACACATTTCAAGCCCCAAA-3′ (BRAF-F), 5′-GAAACTGGTTTCAAAATATTCGTT-3′ (BRAF-R), 5′-AGGCCTGCTGAAAATGACTGAATA-3′ (KRAS-F), 5′-CTGTATCAAAGAATGGTCCTGCAC-3′ (KRAS-R), 5′-CCCCTCCATCAACTTCTTCA-3′ (PIK3CA-2F), 5′-AAAAGCCGAAGGTCACAAG-3′ (PIK3CA-2R), 5′-GACAAAGAACAGCTCAAAGCAA-3′ (PIK3CA-10F), 5′-TTTAGCACTTACCTGTGACTCCA-3′ (PIK3CA-10R), 5′-GAGCAAGAGGCTTTGGAGTA-3′ (PIK3CA-21F), 5′-ATCCAATCCATTTTTGTTGTCC-3′ (PIK3CA-21R), 5′-ACTGTTTCGGTTGGCTTGGTGA-3′ (GNAS-8F), 5′-AGGGACTGGGGTGAATGTCAAGA-3′ (GNAS-8R), 5′-GACATTCACCCCAGTCCCCTCTGG-3′ (GNAS-9F) and 5′-GAACAGCCAAGCCCACAGCA-3′ (GNAS-9R).
Thermal cycling conditions were 5 min at 94°C, followed by 35 cycles of 94°C for 30 seconds, 55°C (β-catenin, GNAS), 53°C (BRAF), 60°C (KRAS) or 58°C (PIK3CA) for 30 seconds and 72°C for 30 seconds followed by a final incubation at 72°C for 7 minutes. The PCR products were ethanol precipitated, washed and subjected to bidirectional dye-terminator sequencing using the PCR amplification primers. After repeated ethanol precipitation of dye labeled DNA fragments, analyses by capillary electrophoresis on a 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA) were performed. Sequence electropherograms were analyzed by Sequence Analysis 5.2 software (Applied Biosystems), followed by manual alignment to the GenBank® reference sequences (β-catenin: X87838, BRAF: M95712, KRAS: BC010502, PIK3CA: U79143 and GNAS: X56009.
Immunohistochemical staining revealed positivity of the tumor cells for Pan-CK, CK7, CK8/18 (Figure 2E), MUC1, MUC6 (Figure 2F), CD10 (Figure 2G), carbonic anhydrase IX (Figure 2H) and EMA. CD10 staining was expressed only focally and with faint intensity (Figure 2G). E-cadherin and β-catenin showed exclusively a membranous staining. MUC2, MUC5AC, vimentin, chromogranin A, synaptophysin, CEA, Hep Par1, neurone specific enolase, GLUT1, CK5/6, HMB45, CD56, estrogen-receptor, progesteron-receptor, RCC, inhibin, FLT 4, CDX 2, cyclin D1, trypsin and chymotrypsin were not detectable. A few tumor cell nuclei were faintly stained for p53, but not indicative for a p53 mutation. Ki67 proliferation index reached focally 10-15%. DNA sequencing demonstrated wild type sequences for β-catenin, BRAF, PIK3CA, GNAS and the KRAS gene. Based on the above findings and in cooperation with two reference pathologists for pancreas neoplasms, the diagnosis of “ITPN with clear cell morphology” was established.
Discussion and conclusions
So far 24 cases of ITPN arising in the pancreas and 13 cases arising in the bile duct have been reported [1, 4–12]. All these cases showed the characteristic ITPN morphology with tubulopapillary growth pattern, absence of acinar differentiation and no detectable secreted mucin. All these features were also detectable in the case presented here but unlike the other ITPN cases, this tumor here consisted of tumor cells with abundant clear cytoplasm that has to the best of our knowledge, not been reported in the literature so far. Intraductal papillary mucinous neoplasm (IPMN), pancreatic intraepithelial neoplasia (PanIN), mucinous cystic neoplasm of the pancreas (MCN), acinar cell carcinoma, solid-pseudopapillary neoplasm (SPN) and tumor metastasis of renal cell carcinoma (RCC) were considered as possible differential diagnosis. In our eyes the most difficult discrimination lies between ITPN and IPMN pancreatobiliary type (PB type) [1, 13, 14]. However, MUC5AC expression, which was not detectable in our case, is considered to be a hallmark for IPMN (Table 1) . Mutational analyses in IPMNs and intraductal carcinoma revealed also a very high frequency (up to 80%) of KRAS and GNAS (up to 60%) mutations [1, 2, 5]. Since in our tumor we detected wild-type sequences for KRAS, GNAS, β-catenin, BRAF this favors ITPN .
Acinar cell carcinoma, also a potential differential diagnosis, was not considered since neither did the tumor cells stain with PAS nor were immunohistochemical markers of pancreatic exocrine enzymes like trypsin and chymotrypsin observable. As well, PanIN was disregarded due to the size of the lesion and the lack of small epithelial papillae . In SPN a combination of solid and pseudopapillary growth pattern is frequently present but these tumors are usually immunoreactive for CD10, vimentin, chromogranin A and nuclear β-catenin [16, 17]. Although a clear cell variant and a chromogranin A negative SPN has already been reported, our case did not show nuclear β-catenin nor vimentin expression, therefore ruling out SPN [16, 18]. MCN is not connected to the pancreatic duct system and contains epithelium (in rare cases squamous epithelium), surrounded by an ovarian-like stroma that stains positive for progesterone receptor, inhibin, CEA, and chromogranin A . Moreover, the epithelial component of MCN is positive for MUC5AC and negative for MUC1 and MUC2, obviously in difference to our results [2, 20]. Metastasis of an extrapancreatic primary clear cell tumor, particularly renal RCC was seriously considered especially since CD10 expression was expressed focally and with faint intensity, however no invasiveness and the absence of vimentin positivity argues against pancreatic metastases of RCC. In addition, the profile of expressed mucins, several tumor free MRI scans of the kidneys and the uneventful clinical follow-up for now over two years rule out RCC metastases .
The molecular basis of clear cell morphology in the presented tumor is unknown and only a few studies discussed genesis of clear cell morphology. So far, the best studied tumor in this context is clear cell RCC and hypoxia regulatory factors have been identified as driving force for the clear cell phenotype . HIF-1α, carbonic anhydrase IX, and GLUT1 have been described as markers for the hypoxia-inducible factor pathway . In the current case we were able to detect a strong staining against carbonic anhydrase IX (FLT4 or GLUT1 were negative) arguing that the clear cell phenomenon in our case might also be associated with hypoxia. However, we cannot rule out that carbonic anhydrase IX, which can also been seen in normal stomach, liver and gallbladder may simply represent a differentiation towards the pyloropancreatic pathway of intraductal papillary neoplasms. Basturk and colleagues claimed that the tubular/tubulopapillary pathway of ITPN forms a subgroup within the pyloropancreatic pathway .
In conclusion, we consider this tumor as ITPN with very unusual clear cell morphology. Recognition of similar tumor cases and clinico-pathological correlations are needed to illuminate the clinical relevance of this obviously rare ITPN subgroup.
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We thank Prof. Günter Klöppel (Consultation Center for Pancreatic and Endocrine Tumors, Department of Pathology, Technical University Munich) for his expert advice and his support in establishing the diagnosis. We also thank Ms. Katrin Wolk for superior technical assistance in immunohistochemistry and Ms. Stefanie Ahls for assistance in image preparation.
- Yamaguchi H, Shimizu M, Ban S, Koyama I, Hatori T, Fujita I, Yamamoto M, Kawamura S, Kobayashi M, Ishida K, et al.: Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2009, 33: 1164-1172. 10.1097/PAS.0b013e3181a162e5.PubMedView Article
- Bosman F, Carneiro F, Hruban RH, Theise ND: WHO Classification of Tumours of the Digestive System. 2010, Lyon: IARC, 304-313.
- Matthaei H, Schulick RD, Hruban RH, Maitra A: Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2011, 8: 141-150. 10.1038/nrgastro.2011.2.PubMedPubMed CentralView Article
- Chang XY, Lu ZH, Li XQ, Chen J: Intraductal tubulopapillary neoplasm of the pancreas: a clinicopathologic study of 6 cases. Zhonghua Bing Li Xue Za Zhi. 2013, 42: 248-251.PubMed
- Yamaguchi H, Kuboki Y, Hatori T, Yamamoto M, Shimizu K, Shiratori K, Shibata N, Shimizu M, Furukawa T: The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant. J Pathol. 2013, 231: 335-341.PubMedView Article
- Tajiri T, Tate G, Matsumoto K, Hoshino H, Iwamura T, Kodaira Y, Takahashi K, Ohike N, Kunimura T, Mitsuya T, Morohoshi T: Diagnostic challenge: intraductal neoplasms of the pancreatobiliary system. Pathol Res Pract. 2012, 208: 691-696. 10.1016/j.prp.2012.09.002.PubMedView Article
- Guan H, Gurda G, Marie Lennon A, Hruban RH, Erozan YS: Intraductal tubulopapillary neoplasm of the pancreas on fine needle aspiration: case report with differential diagnosis. Diagn Cytopathol. in press
- Jokoji R, Tsuji H, Tsujimoto M, Shinno N, Tori M: Intraductal tubulopapillary neoplasm of pancreas with stromal osseous and cartilaginous metaplasia; a case report. Pathol Int. 2012, 62: 339-343. 10.1111/j.1440-1827.2012.02791.x.PubMedView Article
- Zen Y, Amarapurkar AD, Portmann BC: Intraductal tubulopapillary neoplasm of the bile duct: potential origin from peribiliary cysts. Hum Pathol. 2012, 43: 440-445. 10.1016/j.humpath.2011.03.013.PubMedView Article
- Park HJ, Jang KT, Heo JS, Choi YL, Han J, Kim SH: A potential case of intraductal tubulopapillary neoplasms of the bile duct. Pathol Int. 2010, 60: 630-635. 10.1111/j.1440-1827.2010.02572.x.PubMedView Article
- Yamaguchi H, Kuboki Y, Hatori T, Yamamoto M, Shiratori K, Kawamura S, Kobayashi M, Shimizu M, Ban S, Koyama I, et al.: Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. Am J Surg Pathol. 2011, 35: 1812-1817. 10.1097/PAS.0b013e31822769a0.PubMedView Article
- Katabi N, Torres J, Klimstra DS: Intraductal tubular neoplasms of the bile ducts. Am J Surg Pathol. 2012, 36: 1647-1655. 10.1097/PAS.0b013e3182684d4f.PubMedView Article
- Konigsrainer I, Glatzle J, Kloppel G, Konigsrainer A, Wehrmann M: Intraductal and cystic tubulopapillary adenocarcinoma of the pancreas–a possible variant of intraductal tubular carcinoma. Pancreas. 2008, 36: 92-95. 10.1097/MPA.0b013e318149f536.PubMedView Article
- Tajiri T, Tate G, Kunimura T, Inoue K, Mitsuya T, Yoshiba M, Morohosh T: Histologic and immunohistochemical comparison of intraductal tubular carcinoma, intraductal papillary-mucinous carcinoma, and ductal adenocarcinoma of the pancreas. Pancreas. 2004, 29: 116-122. 10.1097/00006676-200408000-00006.PubMedView Article
- Ott C, Heinmoller E, Gaumann A, Scholmerich J, Klebl F: Intraepithelial neoplasms (PanIN) and intraductal papillary-mucinous neoplasms (IPMN) of the pancreas as precursor lesions of pancreatic carcinoma. Med Klin (Munich). 2007, 02: 127-135.View Article
- Keogan MT, Tyler D, Clark L, Branch MS, McDermott VG, DeLong DM, Coleman RE: Diagnosis of pancreatic carcinoma: role of FDG PET. AJR Am J Roentgenol. 1998, 171: 1565-1570. 10.2214/ajr.171.6.9843289.PubMedView Article
- Ariyama J, Suyama M, Satoh K, Wakabayashi K: Endoscopic ultrasound and intraductal ultrasound in the diagnosis of small pancreatic tumors. Abdom Imaging. 1998, 23: 380-386. 10.1007/s002619900365.PubMedView Article
- Guan ZW, Sun L, Wang YQ, Xu BX: Solid pseudopapillary tumor of the pancreas and concomitant urogenital malformations in a young woman. Diagn Pathol. 2013, 8: 35-10.1186/1746-1596-8-35.PubMedPubMed CentralView Article
- Li P, Wang Y, Zhang Q, Liu Y, Lv Y, Wang Z: A noninvasive mucinous cystic neoplasm with intermediate-grade dysplasia of the pancreas and extensive squamous metaplasia: a case report with clinicopathological correlation. Diagn Pathol. 2012, 7: 89-10.1186/1746-1596-7-89.PubMedPubMed CentralView Article
- Nakamura A, Horinouchi M, Goto M, Nagata K, Sakoda K, Takao S, Imai K, Kim YS, Sato E, Yonezawa S: New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy. J Pathol. 2002, 197: 201-210. 10.1002/path.1109.PubMedView Article
- Luttges J, Vogel I, Menke M, Henne-Bruns D, Kremer B, Kloppel G: Clear cell carcinoma of the pancreas: an adenocarcinoma with ductal phenotype. Histopathology. 1998, 32: 444-448. 10.1046/j.1365-2559.1998.00411.x.PubMedView Article
- Guo G, Gui Y, Gao S, Tang A, Hu X, Huang Y, Jia W, Li Z, He M, Sun L, et al.: Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet. 2012, 44: 17-19.View Article
- Rohan SM, Xiao Y, Liang Y, Dudas ME, Al-Ahmadie HA, Fine SW, Gopalan A, Reuter VE, Rosenblum MK, Russo P, Tickoo SK: Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol. 2011, 24: 1207-1220. 10.1038/modpathol.2011.80.PubMedView Article
- Basturk O, Khayyata S, Klimstra DS, Hruban RH, Zamboni G, Coban I, Adsay NV: Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis. Am J Surg Pathol. 2010, 34: 364-370. 10.1097/PAS.0b013e3181cf8bb6.PubMedPubMed CentralView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.